ENTITY
Sihuan Pharmaceutical Hldgs

Sihuan Pharmaceutical Hldgs (460 HK)

42
Analysis
Health CareChina
Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.
more
Refresh

United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable

United Lab is facing a performance decline when the dividend period of the pandemic has subsided. Weight management/veterinary drug businesses have...

Share
10 Feb 2023 08:55

Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook

Continuous M&A fails to bring ideal performance to Haohai. Medical aesthetics is the main growth driver, but Haohai is lack of competitiveness....

Share
29 Nov 2022 08:45

Sihuan Pharmaceutical (460.HK) - About the Recent Business Adjustments and the Outlook

Sihuan's pursuing strategic adjustments actively, but its business transformation may not end up well without persuasive long logic. We recommend...

Share
17 Oct 2022 08:50

Bloomage Biotechnology (688363.CH) - Positioning and Strategic Layout Imply Strong Upside Potential

Synthetic biology/industrial chain integration help Bloomage build high moat.Synergy of multiple business improve the resilience to market...

Share
27 Jul 2022 09:03

Sihuan Pharmaceutical (460.HK) - The Potential Disposal of Generic Drug Business and the Outlook

The medical aesthetics/innovative drug business face various challenges.Though Sihuan is undervalued,concerns on outlook/development mode will...

Share
x